They've had lighter [numbers] in the past two quarters. There might have been some inventory fluctuations that would actually help them and have a small impact on sales numbers on the positive side. Otherwise, I'm expecting numbers to be in line with consensus.
I think the stock will recover.
The interaction of these drugs is not clearly understood.
The long-term effects of that are not known. Many docs have said they'd be cautious prescribing it at first.
Copyright © 2024 Electric Goat Media. All Rights Reserved.